gogo
Amazon cover image
Image from Amazon.com

Foye's principles of medicinal chemistry.

Contributor(s): Material type: TextTextPublisher: Philadelphia : Wolters Kluwer, Lippincott Williams & Wilkins [2013]Edition: Seventh edition; International edition / edited by Thomas L. Lemke, PhD, David A. Williams, Phd ; associate editors, Victoria F. Roche, PhD, S. William Zito, PhDDescription: xviii, 1500 pages : illustrations (black and white) ; 29 cmISBN:
  • 9781451175721 (hbk.) :
  • 9781451175721 (hardback) :
Other title:
  • Principles of medicinal chemistry
Uniform titles:
  • Principles of medicinal chemistry.
Subject(s): DDC classification:
  • 616.0756 FOY
LOC classification:
  • RS403 .P75 2013
Contents:
History and evolution of medicinal chemistry -- Part I: Principles of drug discovery -- 1.Drug discovery from natural products. A. Douglas Kinghorn -- 2.Drug design and relationship of functional groups to pharmacologic activity. Robin M. Zavod and James J. Knittel -- 3.Physicochemical and biopharmaceutical properties of drug substances and pharmacokintics. Sunil S. Jambhekar -- 4.Drug metabolism. Davd A. Williams -- 5.Membrane drug transporters. Marilyn E. Morris and Bridget L. Morse -- 6.Pharmaceutical biotechnology. Tanaji T. Talele, Marc Gillespie, and Vijaya L. Korlipara -- 7.Receptors as targets for drug discovery. David A. Johnson and Timothy J. Maher -- 8.Drug discovery through enzyme inhibition. Stephen Kerr -- Part II: Drug receptors affecting neurotransmitters and enzymes as catalytic receptors -- 9.Drugs affecitng cholinergic neurotransmission. E. Kim Fifer -- 10.Andrenergic receptors and drugs affecting anrenergic neurotransmission. Robert K. Griffith -- 11.Serotonin receptors and drugs affecting serotonergic neurotransmission. Richard A. Glennon and Malgorzata Dukat -- 12.Amino acid neurotransmiters in the central nervous systems. Timothy J. Maher -- Part III.Pharmacodynamic agents. Section I: Drugs used to reat neuromuscular disorders: antiparkinsonian and spasmolytic agents. Raymond G. Booth - 14.Antipsychotic and anxiolytic drugs. Raymond G. Booth -- 15.Sedative-hynoptics. Nader H. Moniri -- 16.Anesthetic agents: general and local anesthetics. Timothy J. Maher -- 17.Antiseizure drugs. Barbara Leduc -- 18.Antidepressants. David A. Williams -- 19.Hallucinogenics, stimulants, and related drugs of abuse and their therapeutic potentials. Ricard A. Glennon -- 20.Central analgesics. David A. Williams, Victoria F. Roche, and Edward B. Roche -- Section 2: Drugs affecting the cardiovascular system -- 21.Cardiac agents: cardiac glycosides, antianginal, and antiarrhythmic drugs. Ahmed S. Mehanna -- 22.Diurectics. Peter J. Harvison and Gary O. Rankin -- -- 23.Agents affecting the renin-angiotensin pathway and calcium blockers. Marc Harrold -- 23.Central and peripheral sympatholytics and vasodilators. David A. Williams -- 25.Antihyperlipoproteinemics and inhibitors of cholesterol biosynthesis. Marc Harrold -- 26.Antithrombotics, thrombolytics, antiplatelets and coagulants. Matthias C. Lu -- Section 3: Drugs affecting the hormonal systmes -- 27.Insulin and drugs used to reat diabetes. S. William Zito -- 28.Adrenocorticoids. Duan D. Miller, Robert W. Brueggmeier, and James D. Dalton -- 29.Thyroid function and thyroid drugs. Ali R. Banijamali -- 30.Calcium homeostasis. Robin M. Zavod -- Section 4: Drugs affecting the immune system -- 31.Nonsteroidal anti-inlammatory drugs. Ronal Borne, Mark Levi, and Norman Wilson -- 32.Antihistamines and related antiallergic and antiucler agents. Wndell L. Nelson -- Section 5: Chemotherapeutic agents -- 33.Antibiotics and antimicrobial agents. Elmer J. Gentry -- 34.Antiparasitic agents. Thomas L. Lemke -- 35.Antifungal agents. Thomas L. Lemke -- 37.Cancer and chemotherapy. Victoria F. Roche -- 38.Antiviral agents and proteases inhibitors. Patrick M. Woster -- Part IV.Disease state management -- 39.Asthma and chronic obstructive pulmonary disease. S. William Zito -- 40.Men\'s health. Duane D. Miller, Robert W. Brueggmeier, and James T. Dalton -- 41.Women\'s health. Robin M. Zavod -- 43.Nutrition and obesity. Thomas L. Lemke and David A. Williams.
Summary: This edition places emphasis on patient-focused pharmaceutical care and on the pharmacist as a therapeutic consultant, rather than a chemist. A new disease state management section explains appropriate therapeutic options for asthma, chronic obstructive pulmonary disease, and men's and women's health problems.
Holdings
Item type Current library Call number Copy number Status Date due Barcode
Long Loan TUS: Midlands, Main Library Athlone General Lending 616.0756 FOY (Browse shelf(Opens below)) 1 Available 216881
Long Loan TUS: Midlands, Main Library Athlone General Lending 616.0756 FOY (Browse shelf(Opens below)) 1 Available 216924

Includes Internet access.

Previous edition: published as by Thomas L. Lemke. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins, 2008.

Includes bibliographical references and index.

History and evolution of medicinal chemistry -- Part I: Principles of drug discovery -- 1.Drug discovery from natural products. A. Douglas Kinghorn -- 2.Drug design and relationship of functional groups to pharmacologic activity. Robin M. Zavod and James J. Knittel -- 3.Physicochemical and biopharmaceutical properties of drug substances and pharmacokintics. Sunil S. Jambhekar -- 4.Drug metabolism. Davd A. Williams -- 5.Membrane drug transporters. Marilyn E. Morris and Bridget L. Morse -- 6.Pharmaceutical biotechnology. Tanaji T. Talele, Marc Gillespie, and Vijaya L. Korlipara -- 7.Receptors as targets for drug discovery. David A. Johnson and Timothy J. Maher -- 8.Drug discovery through enzyme inhibition. Stephen Kerr -- Part II: Drug receptors affecting neurotransmitters and enzymes as catalytic receptors -- 9.Drugs affecitng cholinergic neurotransmission. E. Kim Fifer -- 10.Andrenergic receptors and drugs affecting anrenergic neurotransmission. Robert K. Griffith -- 11.Serotonin receptors and drugs affecting serotonergic neurotransmission. Richard A. Glennon and Malgorzata Dukat -- 12.Amino acid neurotransmiters in the central nervous systems. Timothy J. Maher -- Part III.Pharmacodynamic agents. Section I: Drugs used to reat neuromuscular disorders: antiparkinsonian and spasmolytic agents. Raymond G. Booth - 14.Antipsychotic and anxiolytic drugs. Raymond G. Booth -- 15.Sedative-hynoptics. Nader H. Moniri -- 16.Anesthetic agents: general and local anesthetics. Timothy J. Maher -- 17.Antiseizure drugs. Barbara Leduc -- 18.Antidepressants. David A. Williams -- 19.Hallucinogenics, stimulants, and related drugs of abuse and their therapeutic potentials. Ricard A. Glennon -- 20.Central analgesics. David A. Williams, Victoria F. Roche, and Edward B. Roche -- Section 2: Drugs affecting the cardiovascular system -- 21.Cardiac agents: cardiac glycosides, antianginal, and antiarrhythmic drugs. Ahmed S. Mehanna -- 22.Diurectics. Peter J. Harvison and Gary O. Rankin -- -- 23.Agents affecting the renin-angiotensin pathway and calcium blockers. Marc Harrold -- 23.Central and peripheral sympatholytics and vasodilators. David A. Williams -- 25.Antihyperlipoproteinemics and inhibitors of cholesterol biosynthesis. Marc Harrold -- 26.Antithrombotics, thrombolytics, antiplatelets and coagulants. Matthias C. Lu -- Section 3: Drugs affecting the hormonal systmes -- 27.Insulin and drugs used to reat diabetes. S. William Zito -- 28.Adrenocorticoids. Duan D. Miller, Robert W. Brueggmeier, and James D. Dalton -- 29.Thyroid function and thyroid drugs. Ali R. Banijamali -- 30.Calcium homeostasis. Robin M. Zavod -- Section 4: Drugs affecting the immune system -- 31.Nonsteroidal anti-inlammatory drugs. Ronal Borne, Mark Levi, and Norman Wilson -- 32.Antihistamines and related antiallergic and antiucler agents. Wndell L. Nelson -- Section 5: Chemotherapeutic agents -- 33.Antibiotics and antimicrobial agents. Elmer J. Gentry -- 34.Antiparasitic agents. Thomas L. Lemke -- 35.Antifungal agents. Thomas L. Lemke -- 37.Cancer and chemotherapy. Victoria F. Roche -- 38.Antiviral agents and proteases inhibitors. Patrick M. Woster -- Part IV.Disease state management -- 39.Asthma and chronic obstructive pulmonary disease. S. William Zito -- 40.Men\'s health. Duane D. Miller, Robert W. Brueggmeier, and James T. Dalton -- 41.Women\'s health. Robin M. Zavod -- 43.Nutrition and obesity. Thomas L. Lemke and David A. Williams.

This edition places emphasis on patient-focused pharmaceutical care and on the pharmacist as a therapeutic consultant, rather than a chemist. A new disease state management section explains appropriate therapeutic options for asthma, chronic obstructive pulmonary disease, and men's and women's health problems.

Powered by Koha